Eisai scores FDA priority review for bigger Lenvima use in kidney cancer

Eisai's thyroid cancer drug Lenvima stepped into the FDA's fast lane for a new use. The agency granted Lenvima priority review as a treatment for advanced kidney cancer, which could be a much more lucrative indication. More than 61,000 patients will be diagnosed with kidney cancer this year, Eisai says; the approval would cover Lenvima in combination with Novartis' ($NVS) Afinitor in patients who've failed on previous VEGF therapy. Release

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.